Posted on September 19, 2011 by Sitemaster
The Phase III SATURN clinical trial of OGX-011 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after initial chemotherapy with docetaxel + prednisone required men to be randomized to either docetaxel + prednisone + OGX-011 or to docetaxel + prednisone + a placebo. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, custirsen, docetaxel, OGX-011, pain, SATURN, survival, synergy | Leave a comment »
Posted on July 26, 2010 by Sitemaster
There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice:
- Angiogenic effect of a specific statin on prostate cancer development
- Synergistic impact of calcitriol on cryotherapy
- Hybrid imaging techniques and prostate cancer
- GTI-2040 in treatment of CRPC … READ MORE …
Filed under: Drugs in development, Management, Risk, Treatment | Tagged: angiogenesis, calcitriol, cryotherapy, GTI-2040, hybrid, imaging, statin, synergy | Leave a comment »
